Found: 22
Select item for more details and to access through your institution.
A peptide antigen derived from EGFR T790M is immunogenic in non-small cell lung cancer.
- Published in:
- International Journal of Oncology, 2015, v. 46, n. 2, p. 497, doi. 10.3892/ijo.2014.2787
- By:
- Publication type:
- Article
Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes.
- Published in:
- International Journal of Oncology, 2015, v. 46, n. 1, p. 28, doi. 10.3892/ijo.2014.2737
- By:
- Publication type:
- Article
Large-scale expansion of γδ T cells and peptide-specific cytotoxic T cells using zoledronate for adoptive immunotherapy.
- Published in:
- International Journal of Oncology, 2014, v. 45, n. 5, p. 1847, doi. 10.3892/ijo.2014.2634
- By:
- Publication type:
- Article
Aberrant splicing isoforms detected by full-length transcriptome sequencing as transcripts of potential neoantigens in non-small cell lung cancer.
- Published in:
- Genome Biology, 2021, v. 22, n. 1, p. 1, doi. 10.1186/s13059-020-02240-8
- By:
- Publication type:
- Article
Intratumoral peptide injection enhances tumor cell antigenicity recognized by cytotoxic T lymphocytes: a potential option for improvement in antigen-specific cancer immunotherapy.
- Published in:
- Cancer Immunology, Immunotherapy, 2013, v. 62, n. 4, p. 639, doi. 10.1007/s00262-012-1366-6
- By:
- Publication type:
- Article
Suppression of postsurgical recurrence of hepatocellular carcinoma treated with autologous formalin-fixed tumor vaccine, with special reference to glypican-3.
- Published in:
- Clinical Case Reports, 2015, v. 3, n. 6, p. 444, doi. 10.1002/ccr3.279
- By:
- Publication type:
- Article
Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate.
- Published in:
- International Journal of Oncology, 2016, v. 48, n. 5, p. 1794, doi. 10.3892/ijo.2016.3403
- By:
- Publication type:
- Article
Next-Generation Cancer Immunotherapy Targeting Glypican-3.
- Published in:
- Frontiers in Oncology, 2019, p. N.PAG, doi. 10.3389/fonc.2019.00248
- By:
- Publication type:
- Article
Tumor-Infiltrating T Cells Concurrently Overexpress CD200R with Immune Checkpoints PD-1, CTLA-4, and TIM-3 in Non-Small-Cell Lung Cancer.
- Published in:
- Pathobiology, 2021, v. 88, n. 3, p. 218, doi. 10.1159/000511557
- By:
- Publication type:
- Article
High CD62L expression predicts the generation of chimeric antigen receptor T cells with potent effector functions.
- Published in:
- International Immunology, 2024, v. 36, n. 7, p. 353, doi. 10.1093/intimm/dxae015
- By:
- Publication type:
- Article
Epigenetic profiles guide improved CRISPR/Cas9-mediated gene knockout in human T cells.
- Published in:
- Nucleic Acids Research, 2024, v. 52, n. 1, p. 141, doi. 10.1093/nar/gkad1076
- By:
- Publication type:
- Article
Selection of highly responsive T cell receptors by an analysis combining the expression of multiple markers.
- Published in:
- Cancer Science, 2023, v. 114, n. 6, p. 2254, doi. 10.1111/cas.15776
- By:
- Publication type:
- Article
Peptide vaccine as an adjuvant therapy for glypican‐3‐positive hepatocellular carcinoma induces peptide‐specific CTLs and improves long prognosis.
- Published in:
- Cancer Science, 2020, v. 111, n. 8, p. 2747, doi. 10.1111/cas.14497
- By:
- Publication type:
- Article
Efficacy of immunotherapy targeting the neoantigen derived from epidermal growth factor receptor T790M/C797S mutation in non–small cell lung cancer.
- Published in:
- Cancer Science, 2020, v. 111, n. 8, p. 2736, doi. 10.1111/cas.14451
- By:
- Publication type:
- Article
Efficacy of the NCCV Cocktail‐1 vaccine for refractory pediatric solid tumors: A phase I clinical trial.
- Published in:
- Cancer Science, 2019, v. 110, n. 12, p. 3650, doi. 10.1111/cas.14206
- By:
- Publication type:
- Article
Heat shock protein 105 peptide vaccine could induce antitumor immune reactions in a phase I clinical trial.
- Published in:
- Cancer Science, 2019, v. 110, n. 10, p. 3049, doi. 10.1111/cas.14165
- By:
- Publication type:
- Article
Higher human lymphocyte antigen class I expression in early‐stage cancer cells leads to high sensitivity for cytotoxic T lymphocytes.
- Published in:
- Cancer Science, 2019, v. 110, n. 6, p. 1842, doi. 10.1111/cas.14022
- By:
- Publication type:
- Article
Cancer immunotherapy‐targeted glypican‐3 or neoantigens.
- Published in:
- Cancer Science, 2018, v. 109, n. 3, p. 531, doi. 10.1111/cas.13485
- By:
- Publication type:
- Article
Glypican-3 could be an effective target for immunotherapy combined with chemotherapy against ovarian clear cell carcinoma.
- Published in:
- Cancer Science, 2011, v. 102, n. 9, p. 1622, doi. 10.1111/j.1349-7006.2011.02003.x
- By:
- Publication type:
- Article
HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells.
- Published in:
- Cancer Science, 2011, v. 102, n. 5, p. 918, doi. 10.1111/j.1349-7006.2011.01896.x
- By:
- Publication type:
- Article
CD83 expression characterizes precursor exhausted T cell population.
- Published in:
- Communications Biology, 2023, v. 6, n. 1, p. 1, doi. 10.1038/s42003-023-04631-6
- By:
- Publication type:
- Article
Detection and preliminary evaluation of circulating tumor cells in the peripheral blood of patients with eight types of cancer using a telomerase-specific adenovirus.
- Published in:
- Oncology Reports, 2014, v. 32, n. 5, p. 1772, doi. 10.3892/or.2014.3436
- By:
- Publication type:
- Article